NCT07051317

Brief Summary

Changes in retinal hemodynamics play a key role in the development of various eye diseases. Currently, mainstream hemodynamic evaluation techniques have low resolution and poor measurement accuracy, limiting their widespread application. Adaptive optical laser scanning ophthalmoscopy (AO-SLO) can capture retinal vascular images at the cellular level, offering the potential for high-precision retinal hemodynamic evaluation. This project will: ① innovate the AO-SLO blood flow imaging scanning module and acquisition mode, develop algorithms for extracting spatiotemporal signal features from blood flow images, and achieve quantitative analysis of retinal hemodynamics based on AO-SLO; ② construct an in vitro retinal hemodynamic measurement simulation eye, conduct multidimensional AO-SLO hemodynamic measurements, and establish an intelligent model for precise calibration of retinal hemodynamic parameters; ③ conduct AO-SLO-based retinal hemodynamic studies in high myopia, integrating multi-modal ophthalmic imaging to investigate the patterns of changes in retinal vascular structure and blood flow function in high myopia. Ultimately, a new precision measurement imaging technology platform for retinal hemodynamics will be established.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2025

Completed
7 days until next milestone

Study Start

First participant enrolled

June 25, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 4, 2025

Completed
27 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2025

Completed
Last Updated

July 4, 2025

Status Verified

February 1, 2025

Enrollment Period

1 month

First QC Date

June 18, 2025

Last Update Submit

July 2, 2025

Conditions

Keywords

Myopia, High-GradeAdaptive opticsRetinal hemodynamics

Outcome Measures

Primary Outcomes (3)

  • Blood flow velocity in the central arteries and veins of the retina

    Measure the blood flow velocity and flow velocity standard deviation of the central arteries and veins of the retina of the subject using an adaptive optical laser scanning ophthalmoscope.

    7 days after the enrollment

  • The structure of central retinal arteries and veins

    Measure the diameter of the central arteries and veins of the retina, the thickness of the vessel walls, and the wall-to-lumen ratio of the subjects using an adaptive optics laser scanning ophthalmoscope.

    7 days after the enrollment

  • Retinal and choroidal capillary morphological parameters

    Use OCTA to obtain images of superficial and deep capillaries and choroidal capillaries within a 3×3 mm area of the posterior pole of the retina, and use a proprietary algorithm to extract morphological parameters.

    7 days after the enrollment

Secondary Outcomes (5)

  • The examination for anterior segment of eyes

    Baseline

  • Axis of the eye

    Baseline

  • Best corrected vision cutiy

    Baseline

  • Intraocular pressure

    Baseline

  • Fundus color photography

    Baseline

Study Arms (2)

myopia, low and middle grade

myopia, high grade

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The people From Guangzhou, Guangdong Province, China

You may qualify if:

  • Participants must understand the clinical study and voluntarily participate, and sign an informed consent form;
  • Age 18-30 years old, no gender restrictions;
  • Equivalent spherical power≤0D cylindrical power -2.0D to +2.0D, best-corrected visual acuity ≥ 1.0

You may not qualify if:

  • Participants with significant refractive media opacity-related conditions (severe cataracts, vitreous diseases, corneal diseases, etc.) at screening, or unable to complete or cooperate with routine ophthalmic examinations;
  • History of or concurrent conditions such as ptosis, nystagmus, diabetic retinopathy, various macular degeneration, retinal vascular diseases, optic nerve inflammatory diseases, primary angle-closure glaucoma, various secondary glaucoma, amblyopia, or severe strabismus
  • History of previous eye surgery
  • Patients with severe hypertension, diabetes, or other systemic diseases that cause secondary changes in the retina
  • Patients with posterior scleral staphyloma, lacquer cracks, choroidal neovascularization, or Fuchs' spots
  • Pregnant women, breastfeeding women, monocular individuals, and individuals with disabilities.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

MyopiaRefractive Errors

Condition Hierarchy (Ancestors)

Eye Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2025

First Posted

July 4, 2025

Study Start

June 25, 2025

Primary Completion

July 31, 2025

Study Completion

August 31, 2025

Last Updated

July 4, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, ICF, CSR